NCT06478212 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06478212
Title	Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Institut de Recherches Internationales Servier
Indications	IDH-mutant and 1p/19q-codeleted oligodendroglioma oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2 astrocytoma, IDH-mutant, grade 4 astrocytoma, IDH-mutant, grade 3 astrocytoma, IDH-mutant, grade 2
Therapies	Temozolomide + Vorasidenib
Age Groups:	adult \| child \| senior
Covered Countries	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| AUT

Additional content available in CKB BOOST